Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The RIDD trial aims to test whether the progression of Dupuytren’s disease can be halted or slowed by treatment with anti-TNF injection. Currently, Dupuytren’s disease is left to progress until the finger deformity is severe enough to warrant a surgical procedure in hospital. If successful, anti-TNF treatment would prevent loss of hand function and the need for surgery, and would allow patients to be treated conveniently and quickly.


Dupuytren’s disease is a very common condition, affecting 4% of the general UK population. Following the initial appearance of nodules the disease progresses, causing the fingers to curl towards the palm and resulting in significant impairment of hand function. Currently there is no approved treatment for early disease, and patients must wait until the finger has contracted significantly before a surgical procedure is offered. Unfortunately, the condition often returns. Prof Nanchahal’s lab have extensively researched the molecular basis of Dupuytren’s disease by studying tissue that is normally discarded at the time of surgery. Our lab data show that Dupuytren’s disease is a localised inflammatory condition and the cells that produce the excess tissue and cause the contractures are dependent on the cytokine TNF.  Drugs which inhibit TNF (called anti-TNF drugs) are already used widely to treat inflammatory arthritis and inflammatory bowel conditions. 


The first part of the study will test different doses of anti-TNF injected once into the nodules of Dupuytren’s patients due to have hand surgery. We will study the excised tissue in our lab to assess which dose is most effective. For this part of the trial we will be recruiting up to 40 patients with advanced Dupuytren’s contracture. For the second part of the study we will recruit approximately 140 people at the early stages of Dupuytren’s disease. Participants will receive injections of anti-TNF or placebo every 3 months for a year. We will monitor disease progression and hand function over an 18 month period to determine whether these injections can help patients and avoid the need for surgery.

Latest update

Apologies to all those who have been waiting to find out the results of the RIDD trial.

Please click on this link to see a video of Professor Jagdeep Nanchahal presenting at the International Dupuytren Symposium 2021 (Session 6) 1st December 2021.

The message of this presentation is that the RIDD phase 2b clinical trial met the primary endpoint of nodule hardness and the secondary endpoint of nodule size using ultrasound scan, with statistically significant differences between the adalimumab and placebo groups.

The full results have been submitted for publication in a peer reviewed journal and will be shared once this has been accepted and published.

There is also a discussion video which has some interesting questions from the panel and is worth a watch.

Thank you once again to all of those that have been invovled with the RIDD trial.


The trial is registered with the ISRCTN registry:
For updates on the trial see:

Wellcome Trust logo

OCTRU logo

Related research themes